BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Krasnoyarsk
BEGIN:STANDARD
TZOFFSETFROM:+0700
TZOFFSETTO:+0700
TZNAME:+07
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20210712T080000
DTEND;TZID=UTC:20210714T170000
DTSTAMP:20260613T075633
CREATED:20201001T235202Z
LAST-MODIFIED:20201001T235202Z
UID:767-1626076800-1626282000@thebiocalendar.com
SUMMARY:Biotech CEO Summit
DESCRIPTION:Held annually in Napa and Europe\, the Biotech CEO Summits provide high-value\, relationship-building opportunities through informal discussions where personal knowledge\, insights\, and ideas are exchanged with peers. These candid discussions take place in a secure\, confidential setting. \nWho Participates\nBiotech CEO Summits are limited to CEOs focused on leading their organizations through the ever-evolving biotech landscape\, transforming individual companies and the industry as a whole. Non-CEO participants include a select group of industry leaders. \nAbout the Program\nThe program includes fireside chats\, case studies and group discussions that address a range of global issues key to biotech CEOs and their companies. The Summit format facilitates engagement\, discussion and interaction with and between all CEOs. The topics are identified in consultation with the advisory board\, and include discussions on strategy (asset selection\, collaborations\, market approach)\, financing (public and private)\, communications to all audiences (shareholders\, investors\, board of directors\, patients\, regulatory bodies\, and team)\, human resources (board and team development and management)\, and lessons learned during make or break situations. \nParticipant Benefits\nAn important benefit of participating in the Summit is the development of trusted relationships between CEOs and the select group of other industry thought leaders. The program is designed to ensure all CEOs spend quality time together. Everyone is encouraged to participate in the candid discussions\, to share their experiences and to ask questions. All CEOs are invited to suggest topics for discussion. Throughout the Summit\, networking sessions\, dinners and activities provide opportunities for CEOs to meet one-on-one and build relationships.
URL:https://thebiocalendar.com/event/biotech-ceo-summit/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2020/10/download-12.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210715
DTSTAMP:20260613T075633
CREATED:20210617T193753Z
LAST-MODIFIED:20210617T193754Z
UID:2049-1626134400-1626307199@thebiocalendar.com
SUMMARY:2021 STAT Breakthrough Science Summit
DESCRIPTION:Come here for the cutting edge\n\nTechnologies and procedures that would have been science fiction are now the reality of medicine. Our 2021 STAT Breakthrough Science Summit will take you inside these innovations\, examining how they’re being developed\, adopted\, and paid for. We’ll also take a look at the breakthroughs that haven’t yet hit the market\, but have the potential to redefine health and medicine in the years to come.
URL:https://thebiocalendar.com/event/2021-stat-breakthrough-science-summit/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2021/06/download.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210713T130000
DTEND;TZID=UTC:20210713T140000
DTSTAMP:20260613T075633
CREATED:20210616T173135Z
LAST-MODIFIED:20210616T173135Z
UID:2039-1626181200-1626184800@thebiocalendar.com
SUMMARY:Insights: Immunotherapy – Helping Our Bodies Cure Cancer
DESCRIPTION:Community Relations Special Event Partnership \nImmunotherapy—empowering our own immune system to kill tumors—has revolutionized the treatment of cancer. \nImmunotherapy—empowering our own immune system to kill tumors—has revolutionized the treatment of cancer. This evolving form of therapy is designed to prime the body’s own immune system to fight the disease head-on. Doctors report promising results\, including tough-to-treat tumors melting away. For some patients\, such as those with melanoma and lung cancer\, immunotherapy has increased survival rates from months to years. \nHowever\, the treatment doesn’t work for everyone\, and even when it does work initially\, it can lose effectiveness as time goes on. Why do some people respond to treatments and others do not? Which cancers respond best to immunotherapy?\nJoin us to hear from those on the leading edge of immunotherapy research: \n\nHow does immunotherapy work?\nWhy do some cancers turn “blind eye” to immunotherapy?\nWhat does the future hold for expanding the benefit of immunotherapy to more patients?\n\nA Q&A session will follow the presentation and will give you an opportunity to personally connect with our scientists and have your questions answered. \nDon’t miss this chance to connect with our scientists and have your questions answered!
URL:https://thebiocalendar.com/event/insights-immunotherapy-helping-our-bodies-cure-cancer/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Krasnoyarsk:20210713T183000
DTEND;TZID=Asia/Krasnoyarsk:20210713T203000
DTSTAMP:20260613T075633
CREATED:20210608T213448Z
LAST-MODIFIED:20210608T213448Z
UID:2000-1626201000-1626208200@thebiocalendar.com
SUMMARY:The pivotal role of CMC in the drug approval process
DESCRIPTION:Solid state chemistry\, polymorphic forms of the drug and the ability to scale up manufacturing are very important details that define the identity as well as feasibility of a drug. Very minor changes in any or each of these aspects of the drug can pivot chances of scale up\, or a process to launch or acquire approval. Things change on the brink of scale up and manufacturing for commercialization to almost derail approval and this talk will feature case studies in this area. \nEvent Location:\nZoom talk: https://us02web.zoom.us/j/88274227563
URL:https://thebiocalendar.com/event/the-pivotal-role-of-cmc-in-the-drug-approval-process/
END:VEVENT
END:VCALENDAR